Summary by Moomoo AI
Cybin Inc., a clinical-stage biopharmaceutical company, has filed a Form F-10 with the Securities and Exchange Commission (SEC) on December 29, 2023, for a Registration Statement under the Securities Act of 1933. This filing allows Cybin to offer up to $160,000,000 in securities, which may include common shares, warrants, units, debt securities, and subscription receipts. The securities may be offered from time to time over a 25-month period once the Registration Statement becomes effective. Cybin, based in Ontario, Canada, specializes in developing psychedelic therapeutics for mental health conditions. The company has a broad range of research and development programs, including its proprietary deuterated psilocybin analog program, CYB003, and deuterated dimethyltryptamine program, CYB004. Cybin's financial statements indicate a need for ongoing financing to continue its research and development activities, as the company has not yet achieved profitability and has experienced operating losses since its inception.